The New York Times, November 10, 2025: This NYT article describes the different data and opinions regarding FDA Commissioner Makary’s decision to remove the black box from all hormone therapy products for menopause despite risks of cancer and stroke. NCHR president Dr. Diana Zuckerman explains why this is a step backward for women’s health.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
FDA ‘serious’ about hormone therapy changes
Politico, October 28, 2025: Politico predicts FDA will revise black box warnings on hormones for menopause, but it isn’t clear how. NCHR’s Diana Zuckerman explains warnings are needed but require more nuance because the evidence is different for hormone creams compared to pills, and evidence of risks and benefits for pills depend on factors such as the type of hormones and the age, medical history, and other differences in the women.
Read More »Some MAHA Supporters Say CNPV Could Lower FDA Standards
Inside Health Policy, October 23, 2025: Inside Health Policy quotes a MAHA meeting that criticized industry influence over FDA, the impact of user fees, the inappropriate reliance on surrogate endpoints for cancer screening and Alzheimer’s drugs. The Lever FDA report finding that most new drugs are approved on evidence inferior to the FDA’s legal standards. NCHR’s Diana Zuckerman is quoted criticizing the FDA’s new CNVP program that promises extremely fast priority reviews for high-impact drugs.
Read More »Kennedy’s Ties to Ally Leading Vaccine Lawsuits Raise Ethical Concerns
New York Times, Oct. 3, 2025: This NYT investigation shows how RFK Jr’s lawyer and long-time colleague Aaron Siri benefits financially from his influence over RFK and HHS, resulting in vaccine policies and other decisions that harm U.S. patients. NCHR president Diana Zuckerman’s experience is included as an example.
Read More »New Blood Tests for Early Cancer Detection Get Some Love From House Members
MedPage Today, September 18, 2025: This news article describes Energy & Commerce Health Committee hearing on bills that would require Medicare cover Breakthrough devices and controversial Multi-cancer Screening tests. NCHR president Dr. Diana Zuckerman testified, describing the cancer tests as “not ready for prime time” and explaining that the latest research shows they are very inaccurate, with some having a false positive rate over 90%
Read More »